Pulmonix, LLC

Greensboro, North Carolina 27403-4443

6 studies enrolling now · 24 studies all time

What they study most

Chronic Cough, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Cough, IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Lung Cancer, Lung Cancer (Diagnosis), Persistent Cough in IPF, Progressive Pulmonary Fibrosis

Studies at this site

• A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — Recruiting now
• Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) — Recruiting now
• Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry — Recruiting now
• DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) — Recruiting now
• Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier — Recruiting now
• Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis — Stopped early
• Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease — Enrolling by invitation
• Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection — Completed
• A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Running, not enrolling
• Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis — Completed
• A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease — Stopped early
• Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis — Completed
• Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis — Completed
• A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis — Completed
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care — Stopped early
• Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer — Completed
• Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF — Stopped early
• Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis — Completed